BlueRock gets rights to cardiac stem cell technologies

14 December 2016

Within days of being launched, BlueRock Therapeutics, a stem cell research company established by German pharma major Bayer (BAYN: DE) and Versant Ventures, has entered into an in-licensing deal.

US clinical-stage biopharma firm VistaGen Therapeutics (Nasdaq: VTGN) has signed an exclusive sublicense agreement with BlueRock, for VistaGen's rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.

VistaGen licensed exclusive rights of the cardiac stem cell technologies from University Health Network (UHN), Canada's largest research hospital, under a strategic research agreement with UHN and distinguished UHN researcher, Dr Gordon Keller, director of UHN's McEwen Center for Regenerative Medicine, one of the world's leading centers for stem cell and regenerative medicine research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK